Immune‐related adverse reactions in the hepatobiliary system: second‐generation check‐point inhibitors highlight diverse histological changes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: Immune check‐point inhibitors are known to cause immune‐mediated adverse liver injury, but our knowledge is mainly based on cases treated with ipilimumab or nivolumab. Methods and results: Clinicopathological features of 10 patients with hepatobiliary adverse reactions caused by second‐generation drugs, pembrolizumab (n = 6) and atezolizumab (n = 4), were reviewed. Liver dysfunction developed during a median period of 3.5 weeks after administration of the check‐point inhibitor (3 days–1 year). Antinuclear antibodies were detected in two patients at a low titre (1/80), and serum IgG concentrations were also only mildly elevated in two patients. Liver biopsies showed panlobular hepatitis (n = 5), cholangiopathic changes (n = 2), granulomatous injury (n = 2) and bland cholestasis (n = 1). Two cases of cholangiopathy (both pembrolizumab‐treated) showed diffuse sclerosing cholangitis on imaging, and one also presented lymphocytic cholangitis resembling primary biliary cholangitis on biopsy. In two atezolizumab‐treated cases, Küpffer cells were hyperplastic and aggregated, forming microgranulomas. Confluent necrosis and eosinophilic or plasma cell infiltration were rare. On immunostaining, the ratio of CD8+/CD4+ cells was 12.2 ± 5.1, which was significantly higher than that in autoimmune hepatitis (2.7 ± 1.1; P < 0.001) or idiosyncratic drug‐induced liver injury (5.0 ± 1.1; P = 0.014). All patients responded to steroid therapy, but it was less effective in patients with sclerosing cholangitis. Conclusions: Pembrolizumab and atezolizumab manifested not only lobular hepatitis but also sclerosing cholangitis, lymphocytic duct injury and granulomatous hepatitis, probably representing various impaired cellular functions in CD8+ lymphocytes and macrophages due to blockage of PD‐1–PD‐L1 interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, jaundice and liver failure are rare in DILI because of ICI, and approximately a third of those with severe grades of DILI may even regress spontaneously.97”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [97]
In the citing paper
“Sclerosing cholangitis is an uncommon manifestation of ICI DILI.96,97”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [97]
In the citing paper
“The predominant histological pattern in ICI DILI is hepatocellular injury, with approximately 70% showing panlobular hepatitis and approximately 20% with centrilobular coagulative necrosis on liver biopsy.95–97”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [97]
In the citing paper
“Unlike AIH, plasma cell infiltration is not predominant, and the inflammatory infiltrate consists mostly of T lymphocytes, with CD8+ cells being greater in number than CD4+ cells.”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1×
“The liver is one of the sites commonly involved in immune-mediated adverse reactions, along with the skin, gastrointestinal tract and endocrine organs.(3,4) Nivolumab (anti-PD1 antibody) and ipilimumab (anti-CTLA-4 antibody) are first-generation drugs that have played a pioneering role in cancer immunotherapy.”
BackgroundSafety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Research works printed but not linked: 24
- 10.1056/NEJMoa1200690 · DOI · Paper page
- 10.1200/JCO.2014.60.0379 · DOI · Paper page
- 10.1056/NEJMoa1606774 · DOI · Paper page
- 10.1056/NEJMoa1501824 · DOI · Paper page
- 10.1038/s41379-018-0013-y · DOI · Paper page
- 10.1097/PAS.0000000000000453 · DOI · Paper page
- 10.1007/s10620-012-2140-5 · DOI · Paper page
- 10.1002/hep.30157 · DOI · Paper page
- 10.1016/j.pathol.2017.07.010 · DOI
- 10.1136/gutjnl-2016-313369 · DOI · Paper page
- 10.1053/j.semdp.2019.07.009 · DOI · Paper page
- 10.1056/NEJMoa1504030 · DOI · Paper page
- 10.1093/annonc/mdq013 · DOI · Paper page
- 10.1055/s-0036-1584319 · DOI
- 10.1097/01.pas.0000136449.37936.6c · DOI · Paper page
- 10.1007/s00535-016-1163-7 · DOI
- 10.1007/s10637-017-0453-0 · DOI · Paper page
- 10.1097/PAS.0000000000000759 · DOI · Paper page
- 10.1159/000362614 · DOI · Paper page
- 10.4161/21624011.2014.954506 · DOI · Paper page
- 10.1200/JCO.2011.39.3298 · DOI · Paper page
- 10.1016/j.jhep.2018.01.033 · DOI · Paper page
- 10.1189/jlb.0113051 · DOI
- 10.1371/journal.pone.0158265 · DOI
Cited by
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
“Chronic liver injury that persists beyond 6– 12 months is observed in 10%–20% of patients with DILI and may be more commonly encountered in those with cholestatic DILI.”
BackgroundInfluentialBerry, P., Kotha, S., Zen, Y., Papa, S., El Menabawey, T., Webster, G., Joshi, D., & Heneghan, M. (2023) · Liver International · doi:10.1111/liv.15340 · Cited by 47
Self-citationNew advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
Yue, M., Li, C., & Li, G. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111799 · Cited by 12
Metadata
- Authors
- Zen, Y., Chen, Y., Jeng, Y., Tsai, H., & Yeh, M. M.
- Affiliations
- Institute of Liver Studies King's College Hospital and King's College London London UK
- Department of Pathology and Laboratory Medicine Taipei Veterans General Hospital Taipei Taiwan
- Department of Pathology National Taiwan University Taipei Taiwan
- Department of Pathology National Cheng‐Kung University Tainan Taiwan
- Department of Pathology University of Washington School of Medicine Seattle WA USA
- ORCID
- Zen, Yoh
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2019-12
- Volume
- 76
- Issue
- 3
- Pages
- 470-480
- ISSN
- 0309-0167
- 1365-2559
- Cited by
- 83
- References
- 6
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.